Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer
[ X ]
Tarih
2017
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Future Medicine Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim: In this study, we aimed to therapeutically target eukaryotic elongation factor 2 kinase (eEF-2K) in an in vivo triple-negative breast cancer (TNBC) tumor model. Materials & methods: We synthesized a highly monodisperse nanoformulation using polyethylenimine-modified gold nanoparticles (AuNP-PEI) as siRNA delivery vehicle and evaluated gene downregulation. Results: We found that AuNP-PEI/eEF-2K nanoformulation was highly effective for in vitro and in vivo gene downregulation and showed remarkable antitumor efficacy that was associated with eEF-2K knockdown, inhibition of Src and MAPK-ERK signaling pathways in a TNBC orthotopic tumor model. Conclusion: Our study suggests that eEF-2K plays an important role in TNBC tumorigenesis and its inhibition by AuNP-PEI/eEF-2K siRNA-based nanotherapeutics may be a potential therapeutic strategy for TNBC.
Açıklama
Shahbazi, Reza/0000-0002-0816-0733
Anahtar Kelimeler
eEF2K, eEF-2K siRNA, eukaryotic elongation factor 2 kinase, nanotherapeutics, PEI-modified gold nanoparticles, triple-negative breast cancer
Kaynak
Nanomedicine
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
12
Sayı
16
Künye
closedAccess
